Clinical trial · Interventional
Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma
Phase II Study of Sorafenib (NSC-724772) and Erlotinib (NSC-718781) in Patients With Advanced Gallbladder Carcinoma or Cholangiocarcinoma
NCT01093222CI-TRIAL-00018408completedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This phase II trial is studying how well giving sorafenib tosylate together with erlotinib hydrochloride works in treating patients with locally advanced, unresectable, or metastatic gallbladder cancer or cholangiocarcinoma. Sorafenib tosylate and erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the tumor.
Conditions
Conditions (9)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Extrahepatic Bile Duct Adenocarcinoma | Extrahepatic Bile Duct Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Gallbladder Adenocarcinoma | Gallbladder Adenocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Gallbladder Adenocarcinoma With Squamous Metaplasia | Gallbladder Adenosquamous Carcinoma | ALIAS | 0.90 |
| Hilar Cholangiocarcinoma | Hilar Cholangiocarcinoma | ONTOLOGY_EXACT | 0.98 |
| Recurrent Extrahepatic Bile Duct Carcinoma | Extrahepatic Cholangiocarcinoma | CURATED_BROADER | 0.78 |
| Recurrent Gallbladder Carcinoma | Gallbladder Carcinoma | CURATED_BROADER | 0.78 |
| Undifferentiated Gallbladder Carcinoma | Gallbladder Undifferentiated Carcinoma |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Erlotinib Hydrochloride | Drug | Erlotinib Hydrochloride | ALIAS |
| Sorafenib Tosylate | Drug | Sorafenib Tosylate | ALIAS |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Treatment (sorafenib tosylate and erlotinib hydrochloride)
- description
- Patients receive sorafenib tosylate PO twice daily and erlotinib hydrochloride PO once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
- interventionNames
- Drug: Erlotinib Hydrochloride
- Drug: Sorafenib Tosylate
Primary outcomes (1)
- measure
- Progression-free Survival
- timeFrame
- Up to 3 years
- description
- From date of registration to date of first documentation of progression or symptomatic deterioration (as defined in protocol), or death due to any cause. Patients last known to be alive and progression free are censored at date of last contact.
Secondary outcomes (3)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Cytologically or pathologically confirmed gallbladder carcinoma or cholangiocarcinoma * No ampullary carcinoma * Locally advanced unresectable or distant metastatic disease * Measurable disease * Patients with biliary obstruction must have decompression of the biliary tree by ERCP and stenting or percutaneous drainage * No prior systemic treatment for metastatic or unresectable locally advanced disease * No known brain metastases * Zubrod performance status of 0-1 * Leukocyte count ≥ 3,000/mm\^3 * ANC ≥ 1,000/mm\^3 * Platelet count ≥100,000/mm\^3 * Total serum bilirubin ≤ 1.5 times upper limit of normal (ULN) * For patient who had decompression of the biliary tree within the past 14 days, stability of the bilirubin level needs to be confirmed with two measurements within 5 to 7 days of each other * Serum albumin ≥ 2.5 g/dL * AST and ALT ≤ 2.5 times ULN (≤ 5 times ULN for liver metastases) * Creatinine clearance ≥ 60 mL/min * Not pregnant or nursing * Fertile patients must agree to use effective contraception * No active biliary sepsis * No bleeding diathesis * No uncontrolled or clinically significant cardiovascular disease, including any of the following: * Myocardial infarction within the past 6 months * Uncontrolled angina within the past 6 months * NYHA class II-IV congestive heart failure * Grade 3 cardiac valve dysfunction * Cardiac arrhythmia not controlled by medication * History of stroke or transient ischemic attack within the past 6 months * History of arterial thrombotic event of any type in the past 6 months * No uncontrolled hypertension, as evidenced by systolic BP ≥ 150 mm Hg or diastolic BP ≥ 100 mm Hg, within the past 28 days * Must be able to swallow and tolerate oral medications * No gastrointestinal tract disease or prior abdominal surgery that results in an inability to absorb oral medication * No other prior malignancy except adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free within the past 3 years * No concurrent grapefruit or its juice * At least 6 months since 1 adjuvant or neoadjuvant regimen of chemotherapy, hormonal therapy, immunotherapy, radiotherapy (to \< 25% of bone marrow only), or chemoradiotherapy before documented recurrence or metastatic disease * No prior treatment with any antiangiogenic agent or any EGFR inhibitors for any reason * Concurrent multiple anti-hypertensive medications allowed * No plans to receive concurrent chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or any other therapy, including herbal or alternative medications for treatment of cancer
References
Publications (0)
Data not yet available
No reference posted for this study.